Everest Medicines’ $448 Million Initial Public Offering


Kirkland has acted as the underwriters’ counsel in the offering.

Everest Medicines Limited (HKSE: 1952) executed its US$448 million IPO and listing on the Hong Kong Stock Exchange. The listing took place on October 9, 2020.

The underwriters included Goldman Sachs, Merrill Lynch, Citigroup, China International Capital Corporation, Credit Suisse, Nomura International and Brocade River Asset Management.

Everest Medicines Limited is a biopharmaceutical company that integrates licensing, clinical development and commercialization of therapies for the needs in Greater China and emerging Asia Pacific.

The Kirkland team advising the underwriters was led by transactional partner David Zhang (Picture) and capital markets partner Li-Chien Wong with assistance from capital markets partner Ben James.

Involved fees earner: Ben James – Kirkland & Ellis; Li-Chien Wong – Kirkland & Ellis; David Zhang – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: Brocade River Asset Management; China International Capital Corporation Limited (CICC); Citigroup Inc.; Credit Suisse; Goldman Sachs; Merrill Lynch, Pierce, Fenner & Smith Incorporated; Nomura;

Author: Michael Patrini